Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration

Ophthalmologica

Volumn 224, Issue 2, 2010, Pages 72-78

  Koss, M J ^a   Scholtz, S ^a   Haeussler Sinangin, Y ^a   Singh, P ^a   Koch, F H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Limited vitrectomy; Occult choroidal neovascularization; Triamcinolone

Indexed keywords

BALANCED SALT SOLUTION; BEVACIZUMAB; TRIAMCINOLONE; TRIAMHEXAL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

ACETATES; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MINERALS; PILOT PROJECTS; PROSPECTIVE STUDIES; SODIUM CHLORIDE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 69049090070     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235724     Document Type: Article

References (34)

1. Korotkin A: An Emerging Problem: Recurrence of CNV in AMD Is Common after Cessation of 24-Month Treatment with Ranibuzumab (Lucentis- ). Fort Lauderdale, ARVO, 2006.
2. Rosenfeld PJ, Rich RM, Lalwani GA: Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-372.
3. Azad R, Chandra P, Gupta R: The economic implications of the use of antivascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007; 55: 441-443.
4. Bradley J, Ju M, Robinson GS: Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10: 141-148.
5. Spaide RF: Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006; 141: 149-156.
6. Augustin AJ, Offermann I: Combination therapy for choroidal neovascularisation. Drugs Aging 2007; 24: 979-990.
7. Barbazetto IA, Liang J, Chang S, Zheng L, Spector A, Dillon JP: Oxygen tension in the rabbit lens and vitreous before and after vitrectomy. Exp Eye Res 2004; 78: 917-924.
8. Holekamp NM, Shui YB, Beebe DC: Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol 2005; 139: 302-310.
9. Stefansson E, Novack RL, Hatchell DL: Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990; 31: 284-289.
10. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S: Posterior vitreomacular adhesion: A potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007; 144: 741-746.
11. Stefansson E: Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009; 247: 147-163.
12. Grossniklaus HE, Green WR: Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496-503.
13. Espinosa-Heidmann DG, Reinoso MA, Pina Y, Csaky KG, Caicedo A, Cousins SW: Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res 2005; 80: 369-378.
14. Penfold PL, Madigan MC, Gillies MC, Provis JM: Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001; 20: 385-414.
15. Chen CY, Wong TY, Heriot WJ: Intravitreal bevacizumab (Avastin- ) for neovascular age-related macular degeneration: a shortterm study. Am J Ophthalmol 2007; 143: 510-512.
16. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
17. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390. (Pubitemid 44197628)
18. Takeda AL, Colquitt JL, Clegg AJ, Jones J: Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007; 91: 1177-1182.
19. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor--1 , platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
20. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614.
21. Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-645.
22. Ruiz-Moreno JM, Montero JA, Barile S: Triamcinolone and PDT to treat exudative agerelated macular degeneration and submacular hemorrhage. Eur J Ophthalmol 2006; 16: 426-434.
23. Spaide RF, Sorenson J, Maranan L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525.
24. Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
25. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G: Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006; 142: 1072-1074.
26. Gottsch JD, Pou S, Bynoe LA, Rosen GM: Hematogenous photosensitization. A mechanism for the development of age-related macular degeneration. Invest Ophthalmol Vis Sci 1990; 31: 1674-1682.
27. Grindle CF, Marshall J: Ageing changes in Bruch's membrane and their functional implications. Trans Ophthalmol Soc UK 1978; 98: 172-175.
28. Blair NP: Ocular oxygen consumption during vitreoperfusion in the cat. Trans Am Ophthalmol Soc 2000; 98: 305-329.
29. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'Amore PA: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor as the mitogen. Mol Med 1995; 1: 182-193.
30. Stefansson E, Landers MB 3rd, Wolbarsht ML: Vitrectomy, lensectomy, and ocular oxygenation. Retina 1982; 2: 159-166.
31. Wilson CA, Benner JD, Berkowitz BA, Chapman CB, Peshock RM: Transcorneal oxygenation of the preretinal vitreous. Arch Ophthalmol 1994; 112: 839-845.
32. Pournaras CJ, Miller JW, Gragoudas ES, Husain D, Munoz JL, Tolentino MJ, Kuroki M, Adamis AP: Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol 1997; 115: 1553-1558.
33. Herbort T, Koss MJ, Julien S, et al: Effects of Combined- vs. Monotherapy in CNV-Induced Albino Rabbits. Poster 743. Annual Meeting of the Association for Research in Vision and Ophthalmology, May 3-7 2009, Fort Lauderdale, USA.
34. Fuseya M, Imamura Y, Ishida S, Inoue M, Tsubota K: Regression of macular drusen after pars plana vitrectomy in a patient with age-related macular degeneration Retina 2007; 1: 160-162.